Moffitt forms immunotherapy CRO

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Moffitt Cancer Center has formed a contract research organization to accelerate the institution’s immunotherapy research.

The subsidiary, which was announced Oct. 3, is intended to provide a one-stop-shop for pharmaceutical and biotech companies to accelerate their immuno-oncology and cell therapy research through collaborative clinical trial support and administration.

“There are currently no other immunotherapy clinical research organizations in the United States. We can provide a much needed service that will bring new immunotherapies to patients more quickly,” Moffit’s Center Director and Executive Vice President at Moffitt, Thomas Sellers, said in a statement.

Moffitt is seeking investment and partnerships to support the wholly-owned, for-profit subsidiary. The cancer center will appoint a board of directors to oversee operations. The CRO is expected to be fully operational in nine to 12 months.

The cancer center has enrolled more than 3,000 patients in immuno-oncology studies over the past five years. The center was involved in clinical trials that led to the approval of CAR T-cell therapy.

The new CRO will offer services that include preclinical study, manufacturing, clinical trial design and oversight, data management and regulatory assistance. The goal is to take a company’s drug or medical device from initial discovery to clinical testing and FDA approval.

“We have a facility certified in Good Manufacturing Practice, a system for ensuring that products are consistently produced and controlled according to quality standards, that is producing these therapies and will establish a network of partners to facilitate multi-center clinical trials,” Brian Springer, Moffit’s vice president and associate center director of research administration, said in a statement.

Table of Contents

YOU MAY BE INTERESTED IN

An updated version of President Trump’s budget request published on May 2 comes as a disappointment for those who hoped that the White House would rethink the draconian cuts contained in an earlier, confidential version of the document that ended up being leaked to the press. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login